Food and Drug
Administration
Transmissible
Spongiform Encephalopathies Advisory Committee
September 19, 2006
Slides
Potential Screening Assays to Detect Blood and Plasma Donors
Infected with TSE Agents: Possible Criteria for Validation,
P. Piccardo, MD, FDA (ppt)
(htm)
Proposed Algorithm for Approval of Human TSE Tests in Europe,
M. Turner, MBChB, PhD, FRCP, FRCPath, University of Edinburgh
(ppt) (htm)
Objective: To define a process such that if an assay method
successfully completes it, it is justifiable to try it in
the Blood Transfusion Service at some scale. (ppt)
(htm)
Development of Rapid Blood Screening Tests for vCJD, Alex
Raeber, Prionics AG (ppt)
(htm)
Use of PMCA for Biochemical Diagnosis of Prion Diseases,
Claudio Soto, PhD, University of Texas Medical Branch and
Aprion Inc. (ppt) (htm)
The Seprion Separation System: Development of a feasible
blood screening protocol for abnormal prion protein, Stuart
Wilson, Microsens Biotechnologies (ppt)
(htm)
Detection of PrPres in Plasma, H. Perron, Biomerieux (ppt)
(htm)
Pronucleon Amplified Misfolded Protein Diagnostic Assay (AMP-D)
Kenton Lohman, Ph.D., Adlyfe Inc. (ppt)
(htm)
CHIRON Submission, David Peretz, M.Sc., D.Sc. (ppt)
(htm)
Open Public Hearing Speakers
Possible Criteria for Approval of Donor Screening Tests for
vCJD, M. Allene Carr-Greer, MT, ASCP(SBB), AABB (pdf)
Up
| AC Home Page